Kodiak Sciences shares jump after positive Phase 3 DAYBREAK trial results
Kodiak Sciences reported that its Phase 3 DAYBREAK trial in wet age‑related macular degeneration met primary endpoints for both Zenkuda and tabirafusp‑ted, showing vision gains non‑inferior to aflibercept. The news sparked an 8.5% rise in the stock on October 15, 2026, and prompted several analysts to lift their price targets. The company remains pre‑revenue but holds roughly $132 million in cash with a current ratio of about 2.5.
Why it matters
LifeSci Capital raised its target to $145 and Jefferies to $112, indicating a re‑rating of the stock based on the trial data (2). The higher targets suggest investors may price in future revenue from a potential launch, but the company’s cash burn of $46.2 million and net loss of $65.6 million highlight ongoing financial risk (2).
Key facts
- 1Kodiak Sciences stock rose 8.56% on October 15, 2026 (2). timothysykes.com
- 2The Phase 3 DAYBREAK trial met primary endpoints for Zenkuda and tabirafusp‑ted, showing non‑inferior vision gains to aflibercept (2). timothysykes.com
- 3Kodiak reported cash of $132.1 million at quarter‑end June 30, 2026 (2). timothysykes.com
- 4Operating cash outflow for the quarter was about $46.2 million (2). timothysykes.com
- 5Net loss for the quarter was roughly $65.6 million (2). timothysykes.com
- 6Current ratio was near 2.5 (2). timothysykes.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.